New combo therapy for seniors with aggressive breast cancer shows promise in early trial
NCT ID NCT01273610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing how well older adults (60+) with advanced HER2+ breast cancer tolerate a combination of two targeted drugs: lapatinib and trastuzumab. The study enrolled 40 participants and focuses on side effects, especially heart-related issues and severe toxicities. The goal is to see if this drug pair is safe enough for this age group, who are often underrepresented in cancer trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lapatinib (Tykerb) and trastuzumab (Herceptin)
What this could lead to
If successful, this could show that combining these two targeted drugs is safe and tolerable for older adults with advanced HER2+ breast cancer, offering a treatment option for this age group.
What could go wrong
This is a small, early-phase trial focused on safety, not on proving the combination works. Side effects like heart problems or severe toxicities are possible, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
City of Hope Antelope Valley
Lancaster, California, 93534, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Duke University Medical Center
Durham, North Carolina, 27704, United States
-
Lineberger Comprehensive Cancer Center, University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
South Pasadena Cancer Center
Pasadena, California, 91030, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States